According to the Korean government, breast cancer has a survival rate of 90.6% and ታይሮይድ cancer has a rate of 99.7%. Additionally, cancer mortality is steadily declining, with declines of 19% in 2006 and 21% in 2008. With these figures it can be said that በደቡብ ኮሪያ ውስጥ የካንሰር ሕክምና በዓለም ላይ ካሉ ምርጥ የካንሰር ሆስፒታሎች ጋር እኩል ነው።
የሕክምና አማራጮች: Surgery, radiation therapy, chemotherapy, immunotherapy, ዒላማ የተደረገ ቴራፒ, and precision medicine are just a few of the cancer treatments available in Korea. Each type of treatment has a unique set of expenses, which might vary greatly.
በዓለም አቀፍ ደረጃ ፣ የጡት ካንሰር is a major cause for concern, but South Korea has achieved great strides in the field of therapy. The nation’s healthcare system is renowned for its cutting-edge innovations and first-rate medical care, both of which have significantly improved the prognosis for patients with breast cancer.
Genetic test to determine the mutation of the gene BRCA1, BRCA2 (It is recommended to do a test if among the next of kin there were more than 1 case of breast, የያዛት ካንሰር, if the patient is less than 40 years old, etc. Gene mutation increases the risk of breast cancer by 70-85%, ovarian cancer by 22-44%, in addition to this bowel cancer, pancreas, uterus, bile ducts. Children are also recommended to be screened. To reduce the risk of cancer, prescribe medications or perform special procedures.)
Chemotherapy, targeted therapy, immunotherapy. The cost: $ 500 ~ $ 5,000 for 1 course Radiotherapy
የሆርሞን ሕክምና (በምርመራው ላይ በመመስረት)
በደቡብ ኮሪያ ውስጥ የሳንባ ካንሰር ሕክምና
One of the most common and difficult diseases to treat is የሳምባ ካንሰር. However, there has been a tremendous improvement in South Korea’s ability to cure this fatal illness. As a result of its world-class oncology specialists, cutting-edge medical technologies, and robust healthcare system, the nation is currently a top location for lung cancer treatment.
The Lung and የኢሶፈገስ ካንሰር Center at Asan Hospital is the location we suggest as the primary choice for በደቡብ ኮሪያ ውስጥ የሳንባ ካንሰር ሕክምና. በደቡብ ኮሪያ ባለፉት አስር አመታት ተቋሙ በመጀመሪያ ደረጃ የሳንባ ካንሰር ሂደቶችን አድርጓል።
14% of all cancer cases are lung cancer, according to the oncology field. This form of cancer is the second most prevalent among all cancers, after የፕሮስቴት ካንሰር, which is more common in males than women. Moreover, one-fourth of all cancer-related fatalities are attributable to lung cancer. Lung cancer affects 1 in 14 men and 1 in 17 women, despite the fact that smokers have a higher risk of developing it.
Lung cancer can be of two primary forms. About 10% to 15% of instances of lung cancer are small cell lung cancer, or SCLC. NSCLC, often known as አነስተኛ ያልሆነ ህዋስ ሳንባ ካንሰር, is the second form. Doctors categorise this into three groups (adenocarcinoma, squamous cell carcinoma and large cell carcinoma). It accounts for 80–85% of the cases.
የደቡብ ኮሪያ ጉበት ካንሰር programme has become known for its cutting-edge research, cutting-edge medical technology, and multidisciplinary approach. Patients looking for cutting-edge and efficient liver cancer treatments have made the nation a top choice. A wide variety of treatment options are available in South Korean hospitals and medical facilities, including surgery, radiofrequency ablation, chemotherapy, immunotherapy, and targeted therapies.
A Cancer Institute that creates treatments for Breast cancer, Lung cancer, Blood cancer, and የአጥንት ካንሰር is a part of Asan Medical Center. The medical staff of the Asan Cancer Center is highly skilled and focused on treating cancers of the head and neck, stomach, intestines, liver, and lymph nodes. Each year, they carry out 1500 laparoscopic tumour removals, 1900 procedures for people with የሆድ ካንሰር, and 2 000 surgeries for people with breast cancer. The breast is saved in about 70% of breast cancer procedures. If the breast is not preserved after 30% of the surgeries, the doctors reconstruct the breast using implants.
Patients from throughout the globe visit Samsung Medical Center every year for treatment of a wide range of cancers, including የማኅጸን ካንሰር, breast cancer, melanoma, epilepsy, lung cancer, and brain tumours.